Fig. 5
Figure adapted from Xu et al., 2017 and additional published reports [54, 85, 86]
Antiviral potency and breadth of HIV-1 mAbs and multi-specific Abs. HIV-1 mAbs and multi-specific antibodies that are licensed (green), in clinical trials (blue), or in clinical development (purple). Open circles represent earlier variants of antibodies in development that are presented. *Means antibodies were delivered by AAV.